Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.

Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK LBCL) is a rare subtype of non-Hodgkin lymphoma. ALK inhibitors are being tried to treat recurrent/refractory ALK LBCL. A majority of patients with ALK tumors respond to crizotinib, but partial cases ultimately develop resistance about a year later.

Optical limiter with an organic solution sandwiched between a polymer slab and a polymer grating.

An optical limiter was designed and fabricated. The device consists of an organic solution sandwiched between a polymer slab and a transparent relief polymer grating with a triangular groove. At low power the device has a high transmittance because the refractive index of the solution is matched with those of the slab and the grating materials and because the grating does not diffract.